The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted.
Rizzo C., Amata S., Pibiri I., Pace A., Buscemi S., Palumbo Piccionello A. (2023). FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 [10.3390/ijms24097728].
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
Rizzo C.Co-primo
;Amata S.Co-primo
;Pibiri I.Secondo
;Pace A.;Buscemi S.Penultimo
;Palumbo Piccionello A.
Ultimo
2023-04-23
Abstract
The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ijms-24-07728-v2_compressed.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
3.71 MB
Formato
Adobe PDF
|
3.71 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
